Skip to main
NMAD

NMAD P/E Ratio

P/E Ratio as of Jul 6, 2026: -6.53

Average-6.33
Median-6.40
Minimum-7.16
Maximum-5.51
-6.53
0.30 (4.82%)past month
The P/E ratio for NMAD is -6.53 as of Jul 6, 2026. This represents a increase of 76.01% compared to its 12-month average P/E ratio of -3.71. A higher P/E ratio suggests that investors expect strong future earnings growth, while a lower P/E ratio may indicate a potentially undervalued stock or slowing growth.

Lixte Biotechnology Holdings I P/E Ratio Formula = Stock Price ÷ Earnings Per Share (EPS)

Lixte Biotechnology Holdings I’s P/E ratio represents the valuation of the company based on its earnings. It’s calculated by dividing the company’s latest stock price by its diluted earnings per share (EPS) over the past 12 months. The P/E ratio helps investors assess how much they are paying for each dollar of earnings, offering valuable insights when comparing Lixte Biotechnology Holdings I to industry peers.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

NMAD P/E Ratio Historic Data

DateStock priceP/E ratio
Jul 1, 2026$7.67-6.83
Jun 1, 2026$7.21-6.42
May 1, 2026$3.37-2.74
Apr 1, 2026$3.065-2.49
Mar 2, 2026$2.93-2.49
Feb 2, 2026$3.56-3.03
Jan 2, 2026$3.84-3.27

NMAD End of Year P/E Ratio

DateP/E ratioChange
2026-6.53+95.51%
2025-3.34+192.98%
2024-1.14+60.56%
2023-0.71-37.17%
2022-1.13-52.52%
2021-2.38

FAQs About Lixte Biotechnology Holdings I (NMAD) P/E ratio

The latest P/E ratio of NMAD is -6.53, as of Jul 6, 2026. This is calculated based on its current stock price and earnings per share (EPS).

Lixte Biotechnology Holdings I’s last 12-month average P/E ratio is -3.71, compared to its current P/E ratio of -6.53. This reflects a increase of 76.01%.

Lixte Biotechnology Holdings I’s current P/E ratio of -6.53 is higher than its last 12-month average P/E of -3.71. A higher P/E can indicate strong future growth expectations, while a lower P/E might suggest undervaluation.

Lixte Biotechnology Holdings I’s average P/E ratio over the last 3 years is -1.9. Comparing this to the current P/E helps assess recent valuation trends and whether the stock is trading above or below its mid-term historical range.

Lixte Biotechnology Holdings I’s average P/E ratio over the last 5 years is -2.17. A deviation from this historical average may indicate shifts in growth expectations, profitability, or broader market conditions affecting valuation.

Lixte Biotechnology Holdings I (NMAD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.